Malaria cases increase at a slow but continued rate. There is a vital need for new antimalarial treatments able to overcome drug resistance for a more sustained control of the disease.
Basilea Pharmaceutica Ltd. has entered into an asset purchase agreement with Spexis AG for a preclinical program of antibiotics from a novel class, targeting gram-negative bacteria, including multidrug-resistant strains.
Exevir Bio BV has released new data demonstrating that its antibodies are highly potent in neutralizing currently circulating COVID-19 omicron variants.
Researchers from Indian Council of Medical Research and affiliated organizations presented the discovery and preclinical evaluation of OSP-rT2544, being developed for the treatment of salmonella.
Trawsfynydd Therapeutics Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Researchers from Yangzhou University presented the discovery and preclinical characterization of LysZX4-NCA, a new endolysin therapeutic being developed for the treatment of multidrug-resistant highly virulent Klebsiella pneumoniae (MDR-hvKP) infections.
Benzothiozinone (BTZ) compounds are among the new entities under development for their antimycobacterial activity, but information on their efficacy in acute tuberculosis (TB) infection models is still lacking.
Pseudomonas aeruginosa uses the quorum sensing (QS) system to regulate virulence factors expression and biofilm development. Researchers from Jinan University reported on novel inhibitors of P. aeruginosa transcriptional activator proteins LasR and LasB.
RSS
